Compare Micron Technology, Inc. (MU) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs Novartis AG — how do they compare? Micron Technology, Inc. trades at $1,057.68 (market cap $1.23T), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Micron Technology, Inc. is far larger — about 4.5× Novartis AG's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Micron Technology, Inc. for 48 Days and Novartis AG for 82 Days on average.
| MU | NVS | |
|---|---|---|
Market Cap | $1.23T | $274.00B |
Volume | 30,214,899 | 1,852,137 |
Sector | Technology | Health |
52-Week High | $1.21K | $168.62 |
52-Week Low | $181.60 | $121.80 |
Typical Hold Time | 48 Days | 82 Days |
Enterprise Value | $1.19T | $315.32B |
Dividend Yield | 0.06% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,035.84, down 0.93% today but remains in a strong uptrend with a 500% gain over the past year. The stock exhibits bullish technical signals, supported by robust fundamentals including a 379% YoY revenue surge in fiscal 2026 and consistent earnings beats. Analyst sentiment is overwhelmingly positive, with 83% recommending Buy, citing AI-driven memory demand and strategic customer agreements securing future revenue.
Outlook: Micron is positioned for sustained growth through 2030 due to AI memory demand and supply constraints, but risks include cyclical slowdowns and valuation sensitivity. The consensus price target of $1,590 implies 53% upside, though high volatility and competitive pressures warrant caution for new investments.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
